(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 640.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Inovio Pharmaceuticals's revenue in 2025 is $182,337.On average, 3 Wall Street analysts forecast INO's revenue for 2025 to be $3,719,986, with the lowest INO revenue forecast at $3,719,986, and the highest INO revenue forecast at $3,719,986. On average, 4 Wall Street analysts forecast INO's revenue for 2026 to be $804,048,461, with the lowest INO revenue forecast at $58,456,927, and the highest INO revenue forecast at $2,206,483,285.
In 2027, INO is forecast to generate $4,811,536,527 in revenue, with the lowest revenue forecast at $3,119,474,201 and the highest revenue forecast at $6,503,598,853.